Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28652
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFinfer, Simon-
dc.contributor.authorMicallef, Sharon-
dc.contributor.authorHammond, Naomi-
dc.contributor.authorNavarra, Leanlove-
dc.contributor.authorBellomo, Rinaldo-
dc.contributor.authorBillot, Laurent-
dc.contributor.authorDelaney, Anthony-
dc.contributor.authorGallagher, Martin-
dc.contributor.authorGattas, David-
dc.contributor.authorLi, Qiang-
dc.contributor.authorMackle, Diane-
dc.contributor.authorMysore, Jayanthi-
dc.contributor.authorSaxena, Manoj-
dc.contributor.authorTaylor, Colman-
dc.contributor.authorYoung, Paul-
dc.contributor.authorMyburgh, John-
dc.date2022-01-18-
dc.date.accessioned2022-01-28T05:11:39Z-
dc.date.available2022-01-28T05:11:39Z-
dc.date.issued2022-03-03-
dc.identifier.citationThe New England journal of medicine 2022; 386(9): 815-826en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/28652-
dc.description.abstractWhether the use of balanced multielectrolyte solution (BMES) in preference to 0.9% sodium chloride solution (saline) in critically ill patients reduces the risk of acute kidney injury or death is uncertain. In a double-blind, randomized, controlled trial, we assigned critically ill patients to receive BMES (Plasma-Lyte 148) or saline as fluid therapy in the intensive care unit (ICU) for 90 days. The primary outcome was death from any cause within 90 days after randomization. Secondary outcomes were receipt of new renal-replacement therapy and the maximum increase in the creatinine level during ICU stay. A total of 5037 patients were recruited from 53 ICUs in Australia and New Zealand - 2515 patients were assigned to the BMES group and 2522 to the saline group. Death within 90 days after randomization occurred in 530 of 2433 patients (21.8%) in the BMES group and in 530 of 2413 patients (22.0%) in the saline group, for a difference of -0.15 percentage points (95% confidence interval [CI], -3.60 to 3.30; P = 0.90). New renal-replacement therapy was initiated in 306 of 2403 patients (12.7%) in the BMES group and in 310 of 2394 patients (12.9%) in the saline group, for a difference of -0.20 percentage points (95% CI, -2.96 to 2.56). The mean (±SD) maximum increase in serum creatinine level was 36.6±94.0 μmol per liter (0.41±1.06 mg per deciliter) in the BMES group and 36.1±90.2 μmol per liter (0.41±1.02 mg per deciliter) in the saline group, for a difference of 0.5 μmol per liter (95% CI, -4.7 to 5.3) (0.01 mg per deciliter [95% CI, -0.05 to 0.06]). The number of adverse and serious adverse events did not differ meaningfully between the groups. We found no evidence that the risk of death or acute kidney injury among critically ill adults in the ICU was lower with the use of BMES than with saline. (Funded by the National Health and Medical Research Council of Australia and the Health Research Council of New Zealand; PLUS ClinicalTrials.gov number, NCT02721654.).en
dc.language.isoeng-
dc.titleBalanced Multielectrolyte Solution versus Saline in Critically Ill Adults.en
dc.typeJournal Articleen
dc.identifier.journaltitleThe New England journal of medicineen
dc.identifier.affiliationIntensive Care..en
dc.identifier.affiliationGeorge Institute for Global Health, Sydney, Australia..en
dc.identifier.affiliationMalcolm Fisher Department of Intensive Care, Royal North Shore Hospital, Sydney, Australia..en
dc.identifier.affiliationCentral Clinical School, University of Sydney, Sydney, Australia..en
dc.identifier.affiliationIntensive Care Unit, Royal Prince Alfred Hospital, Sydney, Australia..en
dc.identifier.affiliationDepartment of Intensive Care, St. George Hospital, Sydney, Australia..en
dc.identifier.affiliationIntensive Care Unit, Bankstown Hospital, Sydney, Australia..en
dc.identifier.affiliationUniversity of New South Wales, Sydney, Australia..en
dc.identifier.affiliationDepartment of Intensive Care, Royal Melbourne Hospital, Melbourne, Australia..en
dc.identifier.affiliationDepartment of Critical Care, University of Melbourne, Melbourne, Australia..en
dc.identifier.affiliationAustralian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia..en
dc.identifier.affiliationSchool of Public Health, Imperial College London, London, UK..en
dc.identifier.affiliationMedical Research Institute of New Zealand, Wellington, New Zealand..en
dc.identifier.affiliationDepartment of Intensive Care, Wellington Regional Hospital, Wellington, New Zealand..en
dc.identifier.affiliationNorthern Clinical School, University of Sydney, Sydney, Australia..en
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35041780/en
dc.identifier.doi10.1056/NEJMoa2114464en
dc.type.contentTexten
dc.identifier.orcid0000-0002-2785-5864en
dc.identifier.orcid0000-0002-8496-2324en
dc.identifier.orcid0000-0002-6559-7747en
dc.identifier.orcid0000-0002-4975-9793en
dc.identifier.orcid0000-0002-3428-3083en
dc.identifier.orcid0000-0003-4088-7016en
dc.identifier.orcid0000-0002-1650-8939en
dc.identifier.pubmedid35041780-
local.name.researcherBellomo, Rinaldo
item.cerifentitytypePublications-
item.languageiso639-1en-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptIntensive Care-
crisitem.author.deptData Analytics Research and Evaluation (DARE) Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

28
checked on Oct 31, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.